Source |
Code |
Name |
Case count |
Share of cases (%) |
REIMB |
REIMB_KELA(202)_ICD10(M45) |
Connective tissue diseases, rheumatoid arthritis and comparable disease, Ankylosing spondylitis |
1222 |
|
REIMB |
REIMB_KELA(313)_ICD10(M45) |
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Ankylosing spondylitis |
914 |
|
REIMB |
REIMB_KELA(281)_ICD10(M45) |
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Ankylosing spondylitis |
881 |
|
REIMB |
REIMB_KELA(313)_ICD10(M450) |
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases), Name not found |
20 |
|
REIMB |
REIMB_KELA(281)_ICD10(M450) |
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab, Name not found |
18 |
|
REIMB |
REIMB_KELA(202)_ICD10(M450) |
Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found |
11 |
|
REIMB |
REIMB_KELA(202)_ICD9(M45) |
Connective tissue diseases, rheumatoid arthritis and comparable disease, Name not found |
8 |
|
REIMB |
REIMB_KELA(3029)_ICD10(M45) |
Upadacitinib, Ankylosing spondylitis |
5 |
|